AstraZeneca Showcases Broad Advances in Blood Cancer and Rare Disease Care With 65 Presentations at ASH 2025

Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers New ...

December 05, 2025 | Friday | News
Taiho Oncology Europe Announces UK Launch of Lytgobi (Futibatinib) for Eligible Patients With Locally Advanced or Metastatic Cholangiocarcinoma

Taiho Oncology Europe GmbH announced the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibi...

December 04, 2025 | Thursday | News
AdvanCell Initiates TheraPb Phase 2 Expansion Evaluating 212Pb-ADVC001 Following Encouraging Phase 1b Data Presented at ESMO 2025

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion wil...

December 04, 2025 | Thursday | News
Imugene and JW Therapeutics Collaborate on Innovative CF33-CD19 and CAR-T Therapy for Solid Tumors

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlyt...

December 01, 2025 | Monday | News
Arletta Pharma Emerges from Freya Pharma Rebranding to Focus on Women’s Sexual Health

New name reflects company’s transformation as it advances toward the final phase of Lybrido™’s clinical development The Arletta but...

December 01, 2025 | Monday | News
AstraZeneca’s IMFINZI Plus FLOT Receives US Approval as First Neoadjuvant Immunotherapy for Early Gastric and GEJ Cancers

AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxe...

November 27, 2025 | Thursday | News
GE HealthCare Receives FDA Authorization for Pristina Recon DL, a Breakthrough in AI-Enhanced 3D Mammography

GE HealthCare (Nasdaq: GEHC) announced that it has received FDA Premarket Authorization for Pristina Recon DL, an advanced 3D mammography image reconstru...

November 27, 2025 | Thursday | News
Avenzo Therapeutics Receives FDA Fast Track Designation for AVZO-103 in Urothelial Cancer

-Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, announced the U....

November 25, 2025 | Tuesday | News
MiNK Therapeutics Unveils MiNK-215, an IL-15–Armored FAP-Targeting CAR-iNKT With Potent Anti-Tumor Activity

MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills ...

November 24, 2025 | Monday | News
Actimed and Mankind Pharma Sign Exclusive Licensing Deal for Cachexia Treatments in India and South Asia

Covers exclusive rights to S-pindolol, the novel therapy in development for the treatment of cachexia, in India and South Asia Represents a major step...

November 24, 2025 | Monday | News
Thermo Fisher’s Oncomine Dx Target Test Gains FDA Approval as CDx for Bayer’s Newly Approved HYRNUO™

  Test will serve as a companion diagnostic for Bayer’s HYRNUO™ (sevabertinib) to identify patients with NSCLC eligible for HER2-targeted...

November 20, 2025 | Thursday | News
BriaPro Launches AI-Driven Collaboration With Receptor.AI to Design Isoform-Selective Anti-Cancer Kinase Inhibitors

Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partners...

November 21, 2025 | Friday | News
Oncolytics Biotech Gains FDA Agreement on Pivotal Study Design for Pelareorep in First-Line Metastatic Pancreatic Cancer

Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flex...

November 20, 2025 | Thursday | News
PrognomiQ Launches ProVue Lung, a Blood-Based Test Designed for Earlier Lung Cancer Detection

Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network –  Pr...

November 19, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close